Sanofi (SNY) is planning changes to its 340B plan on how it gives discounts to certain hospitals, planning to require institutions to provide pharmacy and medical claims information before receiving federally mandated discounts, The Wall Street Journal’s Jared S. Hopkins reports. The company plans to send a letter, which was reviewed by the publication, to hospitals outlining its new model on Friday, according to people familiar with the matter. Eli Lilly (LLY) and Johnson & Johnson (JNJ) this month filed separate lawsuits against the federal government for rejecting the companies’ plans to tighten the way they provide the discounts to hospitals in the program. Drugmakers currently provide 340B discounts at the time of purchase.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SNY:
- Sanofi’s Sarclisa Nears EU Approval for Myeloma
- Regeneron, Sanofi announce FDA accepts Dupixent sBLA for review
- Deutsche downgrades GSK to Hold on Trump’s RFK nomination
- Biotech Alert: Searches spiking for these stocks today
- Sanofi treatment of acute myeloid leukemia granted orphan status
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
